Beta-blockers for atrial fibrillation: Must we consider asymptomatic arrhythmias?

Journal of the American College of Cardiology

Volumn 36, Issue 1, 2000, Pages 147-150

  Page, Richard L ^a  

^a Texas Cardiac Arrhythmia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATENOLOL; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIDISOMIDE; COUMARIN; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; METOPROLOL; PLACEBO; PROPAFENONE; QUINIDINE; SOTALOL; WARFARIN;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; DRUG EFFICACY; EDITORIAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; SYMPTOMATOLOGY; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ANTICOAGULANTS; ARRHYTHMIA; ATRIAL FIBRILLATION; DECISION MAKING; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HEART ATRIA; HEART RATE; HUMANS; RECURRENCE;

EID: 0033910783     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00676-8     Document Type: Editorial

References (19)

1. Kühlkamp V, Schirdewan A, Stangl K, Homberg M, Matthias P, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized double blind placebo controlled study. J Am Coll Cardiol 2000;36:139-46.
2. Kassotia J., Costeas C., Blitzer M., Reiffel J.A. Rhythm management in atrial fibrillation - with primary emphasis on pharmacologic therapy part 3 . PACE. 21:1998;1133-1145.
3. Prystowsky E.N., Benson D.W., Fuster V., et al. AHA Medical/Scientific Statement Special Report management of patients with atrial fibrillation: a statement for healthcare professionals from the subcommittee on Electrocardiography and Electrophysiology, American Heart Association . Circulation. 93:1996;1262-1277.
4. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group . N Engl J Med. 341:1999;857-865.
5. Pritchett E, Page R, Connolly S, Marcello S, Schnell D, Wilkinson W. Azimilide treatment of atrial fibrillation. Circulation 1998;98:I-633.
6. Anderson J.L., Gilbert E.M., Alpert B.L., et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring . Circulation. 80:1989;1557-1570.
7. Pritchett E.L.C., McCarthy E.A., Wilkinson W.E. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy . Ann Intern Med. 114:1991;539-544.
8. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. Circulation 1997;96:2625-32.
9. Page R.L., Wilkinson W.E., Clair W.K., McCarthy E.A., Pritchett E.L.C. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 89:1994;224-227.
10. Wolk R., Kulakowski P., Karczmarewicz S., et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Int J Cardiol. 54:1996;207-211.
11. Patten M, Maas R. Event-recorder monitoring for differentiation of symptomatic and asymptomatic episodes of paroxysmal atrial fibrillation (abstr). Circulation 1999;100:I-286.
12. DeFaye P, Dournaux F, Mouton E, for the AIDA Multicenter Study Group. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. PACE 1998, part II;21:250-5.
13. Farshi R., Kistner D., Sarma J.S.M., Longmate J.A., Singh B.N. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise a crossover open-label study of five drug regimens . J Am Coll Cardiol. 33:1999;304-310.
14. Chen S.-A., Hsieh M.-H., Tai C.-T., et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation . Circulation. 100:1999;1879-1886.
15. Gallagher M.M., Camm A.J. Classification of atrial fibrillation. PACE. 20:1997;1603-1605.
16. US Department of Health and Human Services, Food and Drug Administration. Proceedings of the cardiovascular and renal drugs advisory committee, 88th meeting, April 29, 1999.
17. Steeds R.P., Birchall A.S., Smith M., Channer K.S. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart. 82:1999;170-175.
18. Edvardsson N, Huikuri H, Kennebäck G, et al. for a European Multicenter Study. Antiarrhythmic efficacy by a class III agent with and without betablockade in chronic atrial fibrillation - a double-blind randomised comparison of DI-sotalol, D-sotalol and placebo (abstracts - oral 706-1 at 10:30). J Am Coll Cardiol 1996;46A.
19. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.